JP6550124B2 - 自閉症スペクトラム障害のリスクを決定するための方法およびシステム - Google Patents

自閉症スペクトラム障害のリスクを決定するための方法およびシステム Download PDF

Info

Publication number
JP6550124B2
JP6550124B2 JP2017504617A JP2017504617A JP6550124B2 JP 6550124 B2 JP6550124 B2 JP 6550124B2 JP 2017504617 A JP2017504617 A JP 2017504617A JP 2017504617 A JP2017504617 A JP 2017504617A JP 6550124 B2 JP6550124 B2 JP 6550124B2
Authority
JP
Japan
Prior art keywords
asd
metabolites
metabolite
level
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510821A5 (cg-RX-API-DMAC7.html
JP2017510821A (ja
Inventor
ウテ ガイガンムーラー，
ウテ ガイガンムーラー，
ドリス ダミアン，
ドリス ダミアン，
マツィエイ パクーラ，
マツィエイ パクーラ，
マーク エー． デプリスト，
マーク エー． デプリスト，
Original Assignee
ラボラトリー コーポレイション オブ アメリカ ホールディングス
ラボラトリー コーポレイション オブ アメリカ ホールディングス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/493,141 external-priority patent/US20150294081A1/en
Application filed by ラボラトリー コーポレイション オブ アメリカ ホールディングス, ラボラトリー コーポレイション オブ アメリカ ホールディングス filed Critical ラボラトリー コーポレイション オブ アメリカ ホールディングス
Publication of JP2017510821A publication Critical patent/JP2017510821A/ja
Publication of JP2017510821A5 publication Critical patent/JP2017510821A5/ja
Application granted granted Critical
Publication of JP6550124B2 publication Critical patent/JP6550124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
JP2017504617A 2014-04-11 2015-04-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム Active JP6550124B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461978773P 2014-04-11 2014-04-11
US61/978,773 2014-04-11
US201462002169P 2014-05-22 2014-05-22
US62/002,169 2014-05-22
US14/493,141 2014-09-22
US14/493,141 US20150294081A1 (en) 2014-04-11 2014-09-22 Methods and systems for determining autism spectrum disorder risk
US14/633,558 2015-02-27
US14/633,558 US9176113B1 (en) 2014-04-11 2015-02-27 Methods and systems for determining autism spectrum disorder risk
PCT/US2015/025247 WO2015157601A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019120817A Division JP2019200210A (ja) 2014-04-11 2019-06-28 自閉症スペクトラム障害のリスクを決定するための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2017510821A JP2017510821A (ja) 2017-04-13
JP2017510821A5 JP2017510821A5 (cg-RX-API-DMAC7.html) 2018-03-22
JP6550124B2 true JP6550124B2 (ja) 2019-07-24

Family

ID=54264902

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017504617A Active JP6550124B2 (ja) 2014-04-11 2015-04-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2019120817A Withdrawn JP2019200210A (ja) 2014-04-11 2019-06-28 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2021042668A Pending JP2021103177A (ja) 2014-04-11 2021-03-16 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2023175239A Withdrawn JP2023178345A (ja) 2014-04-11 2023-10-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2025140823A Pending JP2025172836A (ja) 2014-04-11 2025-08-26 自閉症スペクトラム障害のリスクを決定するための方法およびシステム

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019120817A Withdrawn JP2019200210A (ja) 2014-04-11 2019-06-28 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2021042668A Pending JP2021103177A (ja) 2014-04-11 2021-03-16 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2023175239A Withdrawn JP2023178345A (ja) 2014-04-11 2023-10-10 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
JP2025140823A Pending JP2025172836A (ja) 2014-04-11 2025-08-26 自閉症スペクトラム障害のリスクを決定するための方法およびシステム

Country Status (6)

Country Link
US (3) US9176113B1 (cg-RX-API-DMAC7.html)
EP (2) EP3151665B1 (cg-RX-API-DMAC7.html)
JP (5) JP6550124B2 (cg-RX-API-DMAC7.html)
CN (2) CN113009122B (cg-RX-API-DMAC7.html)
CA (3) CA3030255C (cg-RX-API-DMAC7.html)
WO (1) WO2015157601A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11674948B2 (en) 2014-04-11 2023-06-13 Laboratory Corporation Of America Holdings Methods and systems for determining autism spectrum disorder risk

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019624B1 (en) * 2013-07-09 2020-09-16 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
CN107427221B (zh) * 2015-01-09 2021-03-09 全球基因集团有限责任公司 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
CN108243608A (zh) 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US20190178900A1 (en) * 2016-05-13 2019-06-13 Stemina Biomarker Discovery, Inc. Autism subsets
WO2018089794A1 (en) * 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
EP3756187A4 (en) * 2018-02-19 2021-12-08 The Regents of the University of Colorado, a body corporate OXOPIPERIDE INQUANTIZATION USING MASS SPECTROMETRY
CN112689755A (zh) * 2018-09-11 2021-04-20 梅塔博隆股份有限公司 用于检测和定量微生物区系相关代谢物的质谱测定法
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
US20220163538A1 (en) * 2019-04-05 2022-05-26 Arizona Board Of Regents On Behalf Of Arizona State University Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms
EP3947732A4 (en) * 2019-04-05 2023-01-11 Arizona Board of Regents on behalf of Arizona State University DIAGNOSIS OF MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER
EP3977112A4 (en) * 2019-05-31 2023-09-20 Metabolon Inc. MASS SPECTROMETRY TESTING METHOD FOR DETECTING METABOLITES
BR112022000875A2 (pt) 2019-07-19 2022-03-29 Finch Therapeutics Holdings Llc Métodos e produtos para tratamento de distúrbios gastrointestinais
CN112180005B (zh) * 2020-09-01 2022-10-04 上海市疾病预防控制中心 一种预测鉴定生物样本中酰基肉碱的方法及其应用
WO2022056646A1 (en) * 2020-09-21 2022-03-24 Molecular You Corporation Method of diagnosis and treatment of autism spectrum disorder
CN113539478B (zh) * 2021-06-24 2023-04-07 山西医科大学 基于代谢组学的深静脉血栓形成预测模型的建立方法
CN115938490B (zh) * 2023-03-07 2023-06-06 之江实验室 一种基于图表示学习算法的代谢物鉴定方法、系统和设备

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20050101023A1 (en) 2003-03-28 2005-05-12 Rogers James A. Methods for diagnosing urinary tract and prostatic disorders
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
EP2052255A2 (en) 2006-08-18 2009-04-29 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
CA2693177A1 (en) 2007-07-26 2009-01-29 Phenomenome Discoveries Inc. Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
EP2279417B1 (en) 2008-05-28 2016-07-20 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
GB0912685D0 (en) * 2009-07-22 2009-08-26 Imp Innovations Ltd Methods
MX2012001746A (es) * 2009-08-14 2012-03-21 Univ California Metodos de diagnostico y tratamiento de autismo.
US9547013B2 (en) 2010-04-29 2017-01-17 Wisconsin Alumni Research Foundation Molecule biomarkers of autism
KR20140140069A (ko) * 2012-03-05 2014-12-08 버그 엘엘씨 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
AU2013229381A1 (en) 2012-03-09 2014-09-25 Integragen A genotyping test for assessing risk of autism
US20140045702A1 (en) * 2012-08-13 2014-02-13 Synapdx Corporation Systems and methods for distinguishing between autism spectrum disorders (asd) and non-asd development delay
US10220089B2 (en) * 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11674948B2 (en) 2014-04-11 2023-06-13 Laboratory Corporation Of America Holdings Methods and systems for determining autism spectrum disorder risk

Also Published As

Publication number Publication date
JP2019200210A (ja) 2019-11-21
US9176113B1 (en) 2015-11-03
CN113009122B (zh) 2025-01-17
JP2023178345A (ja) 2023-12-14
CN106714556A (zh) 2017-05-24
JP2021103177A (ja) 2021-07-15
EP3151665A4 (en) 2018-04-25
CA2945528A1 (en) 2015-10-15
CA3030255C (en) 2022-07-05
EP3954991A3 (en) 2022-05-18
EP3151665B1 (en) 2021-03-10
CN113009122A (zh) 2021-06-22
US20240019417A1 (en) 2024-01-18
JP2025172836A (ja) 2025-11-26
CN106714556B (zh) 2021-01-26
EP3954991A2 (en) 2022-02-16
EP3151665A1 (en) 2017-04-12
CA3157221A1 (en) 2015-10-15
CA3030255A1 (en) 2015-10-15
US20160091481A1 (en) 2016-03-31
JP2017510821A (ja) 2017-04-13
CA2945528C (en) 2019-03-12
WO2015157601A1 (en) 2015-10-15
US20150293072A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
JP6550124B2 (ja) 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
US20240133865A1 (en) Methods and Systems for Determining Autism Spectrum Disorder Risk
Jain et al. The handbook of biomarkers
JP7042755B2 (ja) 患者層別化及び潜在的バイオマーカー同定のためのシステム及び方法
US9423403B2 (en) Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
CN108603887A (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
KR20220094201A (ko) 혈액 rna 편집 바이오마커에 의한 양극성 장애와 단극성 우울증의 감별 진단
Liang et al. Novel liquid chromatography-mass spectrometry for metabolite biomarkers of acute lung injury disease
WO2016123058A1 (en) Biomarkers for detection of tuberculosis risk
AU2023308198A1 (en) Methods of assessing dementia risk
HK40051641A (zh) 用於测定自闭症谱系病症风险的方法和系统
EP3295176A1 (en) Biomarkers for detection of tuberculosis risk
HK40065445A (en) Methods and systems for determining autism spectrum disorder risk
WO2025145100A1 (en) Multi-omics assessment

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190628

R150 Certificate of patent or registration of utility model

Ref document number: 6550124

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250